Amyloidosis-related nephropathy Medical Services in China

Amyloidosis-related nephropathy is a progressive kidney disorder caused by the extracellular deposition of misfolded amyloid proteins—primarily immunoglobulin light chains (AL amyloidosis) or serum amyloid A protein (AA amyloidosis)—within the glomeruli, tubulointerstitium, and vasculature of the kidneys. These insoluble fibrillar aggregates disrupt normal renal architecture and function, leading to proteinuria (often nephrotic-range), declining glomerular filtration rate (GFR), hypertension, edema, and ultimately end-stage kidney disease (ESKD) if untreated. Pathogenesis hinges on systemic protein misfolding: in AL amyloidosis, clonal plasma cell dyscrasia produces abnormal light chains that aggregate into β-pleated sheets resistant to proteolysis; in AA amyloidosis, chronic inflammatory conditions (e.g., rheumatoid arthritis, tuberculosis, or familial Mediterranean fever) drive sustained overproduction of serum amyloid A, which fragments and deposits as amyloid. Renal involvement occurs in ~70% of AL amyloidosis cases and up to 90% of AA cases with longstanding inflammation. Epidemiologically, AL amyloidosis has an incidence of 8–12 per million person-years globally, with median age at diagnosis of 65 years; AA amyloidosis is rarer in high-income countries but more prevalent in regions with endemic chronic infections or autoinflammatory disorders. Risk factors include advanced age (>60), monoclonal gammopathy of undetermined significance (MGUS), multiple myeloma, chronic inflammatory or infectious diseases, and certain genetic variants (e.g., SAA1 polymorphisms in AA). Early symptoms are often subtle—fatigue, foamy urine, weight gain from edema—but rapidly progress to hypoalbuminemia, hyperlipidemia, acute kidney injury, and thromboembolic complications due to loss of antithrombin and other plasma proteins. Quality of life is profoundly impaired: patients experience physical debilitation from fluid overload and malnutrition, psychological distress from diagnostic uncertainty and treatment toxicity, social isolation due to fatigue and dialysis dependence, and significant financial burden from prolonged monitoring and multidisciplinary care. Without timely intervention, median survival after renal involvement onset is <2 years in untreated AL amyloidosis. Accurate diagnosis requires kidney biopsy with Congo red staining and immunohistochemistry or mass spectrometry-based typing—critical because therapeutic strategies differ fundamentally between AL and AA subtypes. Early referral to specialized nephrology centers with amyloidosis expertise is essential to optimize outcomes.

Amyloidosis-related nephropathy refers to kidney injury resulting from the extracellular deposition of misfolded amyloid fibrils in renal parenchyma—particularly the glomeruli, interstitium, and vasculature. These insoluble, β-pleated sheet-rich protein aggregates disrupt normal architecture and function, leading to progressive proteinuria, declining glomerular filtration rate (GFR), and eventual end-stage kidney disease. The primary causes are classified by the precursor protein involved: AL (amyloid light-chain) amyloidosis, the most common systemic form affecting the kidneys, arises from clonal plasma cell dyscrasia—typically associated with monoclonal gammopathy of undetermined significance (MGUS), multiple myeloma, or lymphoplasmacytic lymphoma. In AL amyloidosis, immunoglobulin light chains (predominantly lambda isotype) undergo conformational change, aggregate, and deposit as amyloid. AA (amyloid A) amyloidosis, less frequent in high-income countries but still clinically relevant, results from chronic inflammatory or infectious conditions—including rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease, tuberculosis, or chronic osteomyelitis—where sustained elevation of serum amyloid A (SAA) protein leads to proteolytic cleavage and fibril formation. Hereditary (ATTRv) amyloidosis, caused by pathogenic variants in the transthyretin (TTR) gene, may involve renal involvement—especially with Val30Met, Thr60Ala, or Leu111Met mutations—though cardiac and neurological manifestations often predominate; renal deposition occurs via mutant TTR tetramer dissociation and misfolding. Wild-type ATTR (ATTRwt) amyloidosis, previously termed senile systemic amyloidosis, rarely causes significant nephropathy but may contribute to mild proteinuria in elderly males due to age-related TTR instability.

Triggers for renal deterioration include uncontrolled underlying plasma cell disorders (e.g., rising free light chain ratio, increasing bone marrow plasmacytosis), persistent systemic inflammation (e.g., flares of autoimmune disease or untreated chronic infection), and iatrogenic factors such as nephrotoxic medications (NSAIDs, aminoglycosides), volume depletion, or contrast-induced nephropathy—each exacerbating hemodynamic stress on already compromised glomeruli. Acute kidney injury may be precipitated by hypotension, sepsis, or heart failure, particularly in patients with concurrent cardiac amyloid infiltration.

Established risk factors encompass age (peak incidence of AL amyloidosis: 60–75 years; AA: 40–60 years; hereditary forms often manifest earlier, depending on mutation penetrance), male sex (male-to-female ratio ~2:1 in AL and ATTRv), and comorbid chronic inflammatory or hematologic conditions. Patients with long-standing MGUS (>10 years) carry a cumulative risk of progression to AL amyloidosis of ~0.5% per year. Prior autologous stem cell transplantation or alkylator-based chemotherapy increases risk of secondary hematologic malignancy and subsequent amyloidogenesis. Renal risk is further amplified by baseline proteinuria >5 g/day, estimated GFR <60 mL/min/1.73m² at diagnosis, and presence of cardiac involvement (e.g., elevated NT-proBNP, troponin, or echocardiographic strain abnormalities), reflecting multisystem burden and poorer prognosis.

Genetic factors play a central role in hereditary amyloidoses. Over 140 pathogenic TTR variants are documented; Val30Met is most prevalent globally, though non-Val30Met variants (e.g., Ser77Tyr, Glu89Gln) demonstrate higher renal tropism in certain populations. Other rare hereditary forms include apolipoprotein AI (APOA1), fibrinogen Aα-chain (FGA), and lysozyme (LYZ) mutations—all autosomal dominant with variable expressivity and age-dependent penetrance. Polymorphisms in genes regulating protein homeostasis (e.g., HSPB1, DNAJB6) or amyloid clearance (e.g., RAGE, CD36) may modify disease severity but are not currently used in clinical risk stratification.

Environmental exposures are indirect but contributory. Chronic occupational or residential exposure to silica dust or asbestos has been epidemiologically linked to increased systemic inflammation and AA amyloidosis risk. Endemic infections—such as tuberculosis in resource-limited settings or chronic parasitic infestations—sustain SAA elevation. Smoking is associated with accelerated progression in AL amyloidosis, likely via oxidative stress and endothelial dysfunction. Obesity and metabolic syndrome correlate with elevated SAA and interleukin-6 levels, potentially promoting AA deposition. Importantly, delayed diagnosis—often due to nonspecific early symptoms (fatigue, edema, foamy urine) and lack of routine serum free light chain or SAP scintigraphy screening—remains a modifiable environmental/systemic risk factor contributing to irreversible renal damage.

Amyloidosis-related nephropathy is a systemic disorder characterized by extracellular deposition of insoluble, misfolded amyloid fibrils—primarily composed of immunoglobulin light chains (AL amyloidosis) or serum amyloid A protein (AA amyloidosis)—within the renal parenchyma. In the nephrology setting, it represents a significant cause of proteinuric kidney disease and progressive chronic kidney disease (CKD), often culminating in end-stage renal disease (ESRD). Early recognition is critical, as timely diagnosis and targeted therapy can slow progression and improve survival.

Early symptoms are frequently subtle and nonspecific, reflecting subclinical glomerular injury. Patients may report unexplained fatigue, mild peripheral edema (especially periorbital or ankle swelling upon waking), or gradual weight gain attributable to fluid retention. Mild, asymptomatic proteinuria—often detected incidentally on routine urinalysis—is typically the earliest objective finding. Serum albumin levels may begin to decline subtly, while estimated glomerular filtration rate (eGFR) remains preserved or only mildly reduced. Hypertension is uncommon early on, distinguishing it from many other glomerulopathies. Some patients experience vague constitutional symptoms such as low-grade fever, arthralgias, or night sweats—particularly in AA amyloidosis associated with chronic inflammatory conditions (e.g., rheumatoid arthritis, inflammatory bowel disease, or chronic infections).

Typical symptoms emerge as glomerular basement membrane and mesangial matrix become progressively infiltrated with amyloid deposits, leading to podocyte injury, foot process effacement, and disruption of the filtration barrier. Nephrotic-range proteinuria (>3.5 g/24 h) is the hallmark clinical feature, present in over 80% of AL amyloidosis patients with renal involvement. This results in profound hypoalbuminemia (<3.0 g/dL), generalized edema (anasarca), ascites, and pleural effusions. Hyperlipidemia—including elevated total cholesterol, LDL, and triglycerides—is nearly universal due to hepatic upregulation of lipoprotein synthesis in response to hypoalbuminemia. Patients often develop spontaneous bacterial peritonitis secondary to impaired opsonization and complement dysfunction. Renal vein thrombosis occurs in approximately 10–15% of cases, presenting with acute flank pain, hematuria, and sudden worsening of proteinuria or renal function.

Accompanying symptoms reflect multisystem involvement and help guide diagnostic suspicion. Cardiac amyloidosis manifests as dyspnea on exertion, orthopnea, palpitations, or syncope; echocardiography may reveal increased left ventricular wall thickness with preserved ejection fraction and abnormal strain patterns. Peripheral or autonomic neuropathy presents as distal paresthesias, orthostatic hypotension, gastroparesis, or erectile dysfunction. Hepatomegaly, macroglossia (a highly specific sign in AL amyloidosis), and purpura—particularly periorbital ('raccoon eyes')—are suggestive cutaneous or mucosal findings. Carpal tunnel syndrome, often bilateral and refractory, may precede renal manifestations by years. In AA amyloidosis, signs of underlying chronic inflammation (e.g., joint swelling, skin ulcers, or recurrent fevers) dominate the clinical picture.

Complications arise from both direct organ infiltration and secondary pathophysiological consequences. Progressive CKD leads to uremic symptoms: anorexia, nausea, pruritus, cognitive slowing, and pericarditis. Thromboembolic events—including deep vein thrombosis, pulmonary embolism, and stroke—are markedly increased due to loss of antithrombin III and protein S in urine, coupled with amyloid-induced endothelial dysfunction and stasis from hypoalbuminemia. Infections—especially encapsulated organisms (Streptococcus pneumoniae, Haemophilus influenzae)—are frequent owing to impaired opsonization and splenic dysfunction (hyposplenism). Cardiac complications include restrictive cardiomyopathy, arrhythmias (atrial fibrillation, high-grade AV block), and sudden cardiac death. Gastrointestinal involvement may cause malabsorption, bleeding, or pseudo-obstruction. Dialysis-dependent patients face accelerated cardiovascular mortality and heightened infection risk.

Diagnosis requires a high index of suspicion and integration of clinical, laboratory, imaging, and histopathological data. Urinalysis reveals heavy proteinuria, often with lipiduria (oval fat bodies) and hyaline casts; microscopic hematuria is uncommon. Serum studies show hypoalbuminemia, elevated free light chains (FLC) with abnormal kappa/lambda ratio (in AL), and—if AA suspected—elevated serum amyloid A (SAA) and C-reactive protein (CRP). Serum and urine immunofixation electrophoresis (IFE) and FLC assays are mandatory for AL workup. Renal ultrasound typically shows normal or increased kidney size (unlike most chronic glomerulonephritides), with increased cortical echogenicity. Technetium-99m pyrophosphate (PYP) scintigraphy is highly sensitive and specific for cardiac TTR amyloid but not useful for AL or AA. Definitive diagnosis relies on tissue biopsy: renal biopsy remains first-line when feasible, demonstrating Congo red–positive, apple-green birefringent deposits under polarized light, with characteristic non-branching, rigid fibrils on electron microscopy (diameter 7–10 nm). Immunohistochemistry or mass spectrometry-based proteomics is essential to distinguish AL (light chain–positive) from AA (SAA-positive) or other types. If renal biopsy is contraindicated (e.g., severe coagulopathy), abdominal fat pad aspirate has ~75–85% sensitivity for AL and >90% for AA amyloidosis.

Differential diagnosis includes other causes of nephrotic syndrome: minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), membranous nephropathy (MN), and diabetic nephropathy. MCD typically affects children/young adults, lacks systemic features, and shows rapid steroid responsiveness. FSGS demonstrates variable proteinuria, often with hypertension and declining GFR; electron microscopy reveals podocyte foot process effacement without amyloid deposits. MN presents with insidious onset, anti-PLA2R antibodies in ~70–80% of cases, and subepithelial immune complex deposits on biopsy. Diabetic nephropathy occurs in long-standing diabetes, with retinopathy, neuropathy, and characteristic nodular glomerulosclerosis (Kimmelstiel-Wilson lesions). Light chain deposition disease (LCDD) mimics amyloidosis clinically but shows granular, non-fibrillar, kappa- or lambda-restricted deposits on immunofluorescence and electron microscopy. Other amyloid mimics include fibrillary glomerulopathy (larger fibrils, 12–24 nm) and immunotactoid glomerulopathy (microtubular structures). Importantly, AL amyloidosis must be distinguished from monoclonal gammopathy of renal significance (MGRS), which encompasses LCDD, proliferative glomerulonephritis with monoclonal IgG deposits (PGNMID), and cryoglobulinemic glomerulonephritis—all requiring distinct therapeutic approaches. Accurate classification dictates prognosis and management: AL amyloidosis demands hematologic-directed therapy (e.g., daratumumab-based regimens), whereas AA amyloidosis necessitates aggressive control of the underlying inflammatory drive.

Amyloidosis-related nephropathy is a progressive renal complication arising from the systemic deposition of misfolded amyloid fibrils—most commonly immunoglobulin light chains (AL amyloidosis) or serum amyloid A protein (AA amyloidosis)—within the glomeruli, interstitium, and vasculature of the kidneys. This leads to proteinuria, declining glomerular filtration rate (GFR), hypertension, and ultimately end-stage kidney disease (ESKD) if untreated. Management requires a multidisciplinary approach coordinated by nephrologists, hematologists (for AL), rheumatologists (for AA), and pathologists, with early diagnosis via renal biopsy and Congo red staining with apple-green birefringence under polarized light being essential.

Conservative treatment forms the cornerstone of supportive care and aims to mitigate complications while preserving residual renal function. Strict blood pressure control—targeting <130/80 mmHg—is achieved using angiotensin-converting enzyme inhibitors (ACEi) or angiotensin II receptor blockers (ARBs), which reduce intraglomerular pressure and attenuate proteinuria. Sodium restriction (<2 g/day) and fluid management are critical to control edema and prevent volume overload, particularly in patients with nephrotic-range proteinuria (>3.5 g/day). Hyperlipidemia is managed with high-intensity statins (e.g., atorvastatin 40–80 mg daily), given the elevated cardiovascular risk. Nutritional support includes moderate protein intake (0.8–1.0 g/kg/day) to avoid catabolism without exacerbating glomerular hyperfiltration; excessive protein restriction is discouraged. Anemia is addressed with erythropoiesis-stimulating agents (ESAs) and iron supplementation only when ferritin >100 ng/mL and transferrin saturation >20%, avoiding overcorrection. Diuretic therapy (e.g., furosemide plus spironolactone) must be titrated carefully to prevent acute kidney injury or electrolyte derangements. Regular monitoring of serum creatinine, cystatin C–based eGFR, 24-hour urine protein, albumin-to-creatinine ratio (ACR), and cardiac biomarkers (NT-proBNP, troponin) is mandatory for timely intervention.

Pharmacotherapy targets the underlying amyloidogenic process. In AL amyloidosis, first-line therapy is hematologic-directed: daratumumab-based regimens (e.g., daratumumab + cyclophosphamide + dexamethasone [D-CD]) have demonstrated superior hematologic response rates (≥60% very good partial response or better) and improved renal outcomes versus traditional melphalan-dexamethasone. Bortezomib-containing regimens (e.g., CyBorD) remain effective, especially in patients with cardiac involvement. Autologous stem cell transplantation (ASCT) is considered for eligible patients (age <70 years, preserved cardiac function, adequate organ reserve), offering potential deep hematologic remission and renal stabilization. For AA amyloidosis, treatment focuses on suppressing the chronic inflammatory driver—e.g., biologics such as tocilizumab (IL-6 inhibitor) in refractory rheumatoid arthritis or canakinumab (IL-1β inhibitor) in familial Mediterranean fever—thereby reducing SAA production and halting amyloid deposition. Colchicine remains first-line for FMF-associated AA. Novel agents under investigation include NEOD001 (anti-amyloid antibody, though development halted) and CAEL-101 (monoclonal antibody targeting misfolded light chains), currently in Phase III trials.

Surgical treatment is limited but pivotal in select scenarios. Kidney transplantation is feasible in AL amyloidosis only after achieving sustained hematologic remission (≥6 months with negative free light chain ratio and absence of clonal plasma cells on bone marrow biopsy), as recurrence risk is high without disease control. Graft survival at 5 years approaches 75–80% in rigorously selected patients. Combined heart-kidney transplantation may be indicated in AL with concurrent severe cardiac amyloidosis. For AA amyloidosis, transplantation carries lower recurrence risk if inflammation is controlled, and 10-year graft survival exceeds 60%. Surgical debulking is not applicable; however, splenectomy has historical relevance in hereditary amyloidosis (e.g., ATTRv) but no role in AL or AA nephropathy.

China offers distinct advantages in the management of amyloidosis-related nephropathy. First, rapid diagnostic integration is facilitated by nationwide access to advanced renal pathology services—including laser microdissection coupled with mass spectrometry (LMD-MS)—which enables precise amyloid typing in >95% of cases within 7–10 days, surpassing many Western centers in turnaround time. Second, China’s centralized drug approval pathway has accelerated access to novel therapies: daratumumab received NMPA approval for AL amyloidosis in 2022, and biosimilar rituximab and bortezomib are widely available at significantly reduced cost. Third, large-scale clinical registries (e.g., the China Amyloidosis Registry, launched in 2021) support real-world evidence generation and protocol standardization across >120 tertiary nephrology centers. Fourth, integrated Traditional Chinese Medicine (TCM) adjuncts—such as Huangqi decoction (Astragalus membranaceus-based formulas)—are used under evidence-informed protocols to ameliorate proteinuria and fatigue, with randomized trials demonstrating additive antiproteinuric effects when combined with ACEi. Finally, China’s tiered healthcare system ensures seamless referral from community hospitals to national centers (e.g., Peking University First Hospital, Shanghai Renji Hospital), enabling timely initiation of complex regimens.

Recovery and long-term follow-up require structured patient engagement. Patients should undergo quarterly nephrology visits for renal function assessment, biannual hematologic evaluation (serum free light chains, bone marrow studies if indicated), and annual cardiac imaging (echocardiography, cardiac MRI). Vaccination against pneumococcus, influenza, and SARS-CoV-2 is strongly recommended due to immunosuppression-related infection risk. Physical activity should be individualized: aerobic exercise (e.g., brisk walking 30 min/day, 5×/week) improves endothelial function and reduces cardiovascular mortality, but heavy resistance training is discouraged in active nephrotic syndrome. Psychosocial support—including counseling and peer-led support groups hosted by the Chinese Society of Nephrology—is integral, given the high prevalence of depression and treatment-related distress. Smoking cessation and strict alcohol abstinence are non-negotiable. Dietary adherence is reinforced through registered dietitian consultations, emphasizing potassium and phosphorus restriction only upon progression to CKD Stage 4–5. Finally, patients must be educated on early symptom recognition—sudden weight gain (>2 kg/3 days), dyspnea, orthostatic dizziness, or foamy urine—and instructed to seek urgent evaluation to prevent irreversible decompensation. With comprehensive, individualized care, many patients achieve prolonged renal stability and meaningful quality-of-life preservation.